Abstract

ObjectiveTo screen and characterize germline variants for E-cadherin (CDH1) in non-hereditary gastric cancer (GC) patients and in subjects at risk of GC.Methods59 GCs, 59 first degree relatives (FDRs) of GC, 20 autoimmune metaplastic atrophic gastritis (AMAGs) and 52 blood donors (BDs) were analyzed for CDH1 by direct sequencing, structural modelling and bioinformatics. Functional impact on splicing was assessed for intronic mutations. E-cadherin/β-catenin immunohistochemical staining and E-cadherin mRNA quantification using RT-PCR were performed.ResultsIn GCs, 4 missense variants (p.G274S; p.A298T; p.T470I; p.A592T), 1 mutation in the 5′UTR (−71C>G) and 1 mutation in the intronic IVS12 (c.1937-13T>C) region were found. First pathogenic effect of p.A298T mutation was predicted by protein 3D modelling. The novel p.G274S mutation showed a no clear functional significance. Moreover, first, intronic IVS12 (c.1937-13T>C) mutation was demonstrated to lead to an aberrant CDH1 transcript with exon 11 deletion. This mutation was found in 2 GCs and in 1 BD. In FDRs, we identified 4 variants: the polymorphic (p.A592T) and 3 mutations in untranslated regions with unidentified functional role except for the 5′UTR (−54G>C) that had been found to decrease CDH1 transcription. In AMAGs, we detected 2 alterations: 1 missense (p.A592T) and 1 novel variant (IVS1 (c.48+7C>T)) without effect on CDH1 splicing. Several silent and polymorphic substitutions were found in all the groups studied.ConclusionsOverall our study improves upon the current characterization of CDH1 mutations and their functional role in GC and in individuals at risk of GC. Mutations found in untranslated regions and data on splicing effects deserve a particular attention like associated with a reduced E-cadherin amount. The utility of CDH1 screening, in addition to the identification of other risk factors, could be useful for the early detection of GC in subjects at risk (i.e. FDRs and AMAGs), and warrants further study.

Highlights

  • Gastric cancer (GC) remains the fourth most common malignancy worldwide, even though its incidence and associated mortality rates have decreased in recent decades

  • Clinical and histopathological features of GC, first degree relatives (FDRs) and autoimmune metaplastic atrophic gastritis (AMAGs) subjects are summarized in Tables 1 and 2

  • Among the 59 GC patients, 2 (3.4%) have a family history of GC (S15 is the brother of S16) without meeting the criteria for hereditary diffuse GC, as defined by the International Gastric Cancer Linkage Consortium (IGCLC) at the time of sample collection

Read more

Summary

Introduction

Gastric cancer (GC) remains the fourth most common malignancy worldwide, even though its incidence and associated mortality rates have decreased in recent decades. GC prognosis is closely related to the stage of disease at diagnosis [1]. Onset gastric cancer (EOGC) is defined as GC presenting at the age of 45 or younger [2] and has a poor overall survival [3,4]. Most GCs are sporadic and often develop following Helicobacter pylori (HP)-associated gastritis [5,6]. Familial aggregation studies stress the importance of a genetic predisposition in the sporadic development of GC. Frequency of familial gastric aggregation is about 10%

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call